Sepsis and respiratory dysfunction leading to multiple system organ failure remains the leading cause of postoperative morbidity and mortality following major surgical procedures. It has been suggested the oxygen free radicals might play a pivotal role in this process. The aim of this study was to investigate whether short-term infusion of N-acetylcysteine (N-acetylcysteine), a potent antioxidant, administered before and during extensive abdominal surgery, could ameliorate the progression of early postoperative organ dysfunction and improve oxygenation. Out of the 93 patients, 47 received N-acetylcysteine and 46 were given placebo in a randomized, controlled, double-blinded fashion. Patients received N-acetylcysteine (150 mg.kg -1 bolus followed by a continuous infusion of 12 mg.kg -1 .h -1 ) or the same volume of placebo (5% dextrose) during surgery. Treatment effect on organ function was assessed by organ dysfunction scores according to physiological parameters of six main organ systems: respiratory, cardiovascular, renal, hepatic, haematological and central nervous system. The scores were obtained on admission, then daily during the first three postoperative days. For statistical analysis Mann-Whitney U and Chi-squared tests were used. There was no significant difference between the two groups in any of the six organ dysfunction parameters, length of intensive care stay, days of mechanical ventilation and mortality. Our results do not support the routine use of N-acetylcysteine as a prophylactic measure during surgery, and reinforce previous evidence which challenges the indication of N-acetylcysteine in the critically ill.
Sepsis and respiratory dysfunction leading to multiple system organ failure (MSOF) remains the leading cause of postoperative morbidity and mortality following major surgical procedures 1, 2 . Although the complex pathophysiology of MSOF is not known, toxic oxygen free radicals of intracellular as well as extracellular origin seem to play an important role in its development 3 . In patients affected by mild-tomoderate organ dysfunction there is an imbalance between oxidant and antioxidant forces, and it has also been suggested that in MSOF there is an overwhelming production of oxygen free radicals, resulting in tissue destruction 4 . Many authors have proposed the use of exogenous agents such as N-acetylcysteine to prevent oxygen free radical damage in patients suffering from septic shock 5, 6 . N-acetylcysteine acts as a powerful oxygen free radical scavenger, and also replenishes depleted glutathione stores, enhancing the endogenous antioxidant defence 7, 8 . Furthermore N-acetylcysteine inhibits the release of TNF-α, the activation of proinflammatory cytokines, and has been indicated in paracetamol overdose 9, 10 . Recent investigations suggest that early N-acetylcysteine treatment might attenuate the deleterious effect of oxygen free radicals and improve oxygenation in acute respiratory distress syndrome and septic shock 6, 11 . In our recent study we found no overall effect in a heterogeneous ICU population, but a post hoc analysis suggested that N-acetylcysteine may decrease mortality if it is administered within 24 hours of admission 12 . In a previous article it has been reported that N-acetylcysteine treatment increases oxygen consumption in postoperative liver disorders 13 . The authors have also suggested that the value of N-acetylcysteine treatment before major surgery should be evaluated.
In our previous observational study we investigated the predictive value of early organ dysfunction following oesophagectomy 14 . We found that the P a O 2 /FiO 2 ratio measured on the first postoperative day significantly differentiated survivors from nonsurvivors. The P a O 2 /FiO 2 ratio has also been proved to be a sensitive marker of respiratory dysfunction after trauma 15 .
Based on these previous findings we decided to investigate whether N-acetylcysteine treatment administered during surgery could ameliorate the development or progression of postoperative organ dysfunction.
MATERIALS AND METHODS
Following Regional Ethics Committee approval all patients undergoing elective oesophagectomy, total gastrectomy, pancreatectomy (Whipple's operation) or liver resection for tumour removal admitted to our twenty-bed teaching hospital intensive/high dependency care unit were entered the study between October 1999 and October 2001. Each patient gave written informed consent preoperatively. Those who had chronic organ insufficiency prior to their critical illness (as defined by the Acute Physiology and Chronic Health Evaluation (APACHE) II guidelines), whose tumour proved to be inoperable, needed unexpected massive transfusion intraoperatively (>10 units of blood) or required acute re-operation (within 24 hours) were excluded or withdrawn from the study.
After envelope randomization in a block-of-ten, patients enrolled to the N-acetylcysteine group received an IV bolus of N-acetylcysteine of 150 mg.kg -1 in 5% dextrose 250 ml after anaesthesia was induced, followed by 12 mg.kg -1 .h -1 continuous infusion during surgery. Treatment was stopped when anaesthesia was concluded. The placebo group received an equal volume of 5% dextrose. Patients were blinded to the treatment, as were the medical and nursing staff of the ICU.
All patients received routine anaesthetic management and monitoring including premedication with benzodiazepine, induction with propofol, muscle relaxation with atracurium and maintenance with isoflurane, fentanyl and epidural analgesia in the postoperative period. Full blood count, arterial blood gases, cardiorespiratory parameters and blood loss were checked and recorded hourly during surgery.
All patients were observed after surgery for at least two days on the intensive care unit. Routine clinical and biochemical investigations were done. Patients were discharged from ICU if SaO 2 ≥95% on 35% O 2 given via Venturi mask and after establishing good ability of clearing bronchial secretions, multiple organ dysfunction score (MODS) ≤ 2 points, enteral feeding via a jejunostomy tube and adequate analgesia had been established. Each criteria had to be fulfilled for at least 12 hours.
In order to assess the treatment effect on organ function, organ dysfunction scores were recorded as described in the Multiple Organ Dysfunction Scoring System (MODS) by Marshall et al 16 . The scores were obtained on admission, then daily during the first three postoperative days (t 0, 1, 2, 3 ) according to physiological parameters of six main organ systems. The patients' respiratory function was evaluated by the arterial oxygen tension/fraction of inspired oxygen (P a O 2 /FiO 2 ), the cardiovascular system was scored according to heart rate, central venous pressure and mean arterial pressure (HR*CVP/MAP), and renal, hepatic and haematological systems were scored according to serum creatinine, serum bilirubin concentration and platelet count respectively. Neurological function was assessed by the Glasgow Coma Scale.
Statistical analysis
Postoperative mortality related to oesophagectomy is around 10%, and it is even lower in other types of surgery 1,2 . We calculated that for a study to have an 80% power to give a P<0.05 result for a Chi-square test if the N-acetylcysteine treatment's effect on mortality was really 5% (i.e. mortality of 10% for placebo vs 5% for N-acetylcysteine), then the required number of patients was 435/group. This is impossible to achieve in a single-centre trial. Furthermore, although mortality is the most important end-point, it might not be the best outcome measure of treatment effect in critically ill patients.
In a previous descriptive study on a similar patient population we found that the P a O 2 /FiO 2 ratio was the only parameter (biochemical and clinical alike) with significant impact on postoperative mortality 14 . A P a O 2 /FiO 2 >260 torr (34.6 kPa) had a 92% sensitivity for survival.
The mean P a O 2 /FiO 2 in this group was 246± 103 torr (2.7±13.7 kPa) 12 . The "normal" P a O 2 /FiO 2 implying no respiratory dysfunction by the MODS and other scoring systems, is defined as >300 torr (40 kPa). Therefore, the smallest difference between the means we regarded as clinically significant was about 50-60 torr (6.6-8.0 kPa) (i.e. mean 240 torr (32.0 kPa) for placebo and 300 torr (40.0 kPa for Nacetylcysteine). With type I alpha of 5% and type II (power) of 80% we calculated we would need 40 to 60 patients per group. Finally we decided to recruit 50 patients in each group, the number we believed achievable on our ICU within two years. To test normal distribution the Kolgomorov-Smirnov test with Lilliefors' modification was used. When any of the data showed skewed distribution, non-parametric tests were applied. For statistical analysis, Chi-Square test and Mann Whitney U-test was used as appropriate. Changes of the investigated parameters over the study period compared to the baseline were statistically evaluated by Wilcoxon rank sum test. A result was considered to be significant at P<0.05.
RESULTS
One hundred patients were recruited during the two-year study period. However, according to our exclusion criteria, seven were withdrawn from the final analysis (three patients were excluded due to acute re-operation and four due to massive intraoperative transfusion). Out of the remaining 93 patients, 47 received N-acetylcysteine treatment, whilst 46 received placebo.
The two groups were well matched for demographic and clinical characteristics on trial entry ( Table 1 ). The types of the surgical procedures were similar in both groups (Table 1 ). Median length of ICU stay, the length of mechanical ventilation during the total interval of ICU stay and survival were nearly identical in N-acetylcysteine and placebo group ( Table 2) . Seven of 47 patients (15%) in the treatment group and seven of 46 patients (15%) in the placebo group died due to MSOF related to severe pneumonia and in one case the cause of MSOF was mediastinitis caused by the breakdown of the oesophageal anastomosis.
There was no difference between the two groups regarding preoperative risk factors, intraoperative cardiorespiratory parameters, full blood count, arterial blood gas results and blood loss (data not shown).
None of the six organ dysfunction parameters showed a significant difference between the two groups at any time of the study. P a O 2 /FiO 2 ratio was in the normal range in both groups at t 0 and t 1 , then at t 2 and t 3 decreased slightly (but not significantly compared to baseline) without statistically significant difference between the two groups ( ( Table 2) .
DISCUSSION
Systemic inflammatory response leading to postoperative organ dysfunction and sepsis still remain a formidable clinical challenge and carries a significant risk of mortality. Recent clinical studies suggest that patients with sepsis undergo relative oxidative stress 17 . Overwhelming production of oxygen free radicals is thought to play a central role in the inflammatory process 4 . Therefore, the restoration of the endogenous antioxidant mechanisms such as correction of depleted glutathione stores may provide protection from the propagation of oxygen free radicals mediated injury 18 . N-acetylcysteine is a wellknown precursor of glutathione and directly interferes with hydrogen peroxide, hypochloric acid and hydroxyl radical 7, 18 . Further studies demonstrated its ability to modulate inflammatory cell function and cytokine production in vitro and in vivo 9, 11, 19, 20 . Animal studies as well as human trials in accord with our previous findings suggested that early administration (i.e. before induction or development of sepsis) of N-acetylcysteine may improve intracellular gluthatione content, tissue oxygenation, lung injury scores and even survival 5, 6, 11, 12, [18] [19] [20] [21] . Despite these encouraging results the role of N-acetylcysteine in the critically ill remains controversial. Recent randomized placebo controlled studies found no significant differences in gas exchange, development of ARDS and mortality in patients treated with N-acetylcysteine and placebo, in ARDS and early septic shock 19, [21] [22] [23] [24] . Furthermore, several papers reported conflicting and undesirable effects of N-acetylcysteine administration. Depressed cardiac performance was found in septic patients, and impaired bacterial killing due to augmented neutrophil phagocytosis in animals and humans was reported 21, 25, 26 . In our very recent study based on a post hoc analysis, we suggested that N-acetylcysteine may decrease mortality if it was administered within 24 hours of ICU admission, whilst mortality increased in those who received N-acetylcysteine 24 hours after admission 12 .
In the present trial, we have shown that short-term infusion of the oxidant scavenger N-acetylcysteine given on the initiation of the inflammatory process failed to produce effects that were significantly different from placebo. None of the observed clinical or outcome parameters showed significant difference between the two groups. We could not demonstrate beneficial effects of N-acetylcysteine on respiratory function as monitored by the P a O 2 /FiO 2 ratio, or on cardiac or hepatic function. Similar results have been reported in previous studies 6, 11, 21, 22, 27 .
Several factors may have influenced our results. Animal studies showing the benefit of N-acetylcysteine usually follow a protocol of pre-treating the subjects with N-acetylcysteine and then exposing them to endotoxin to produce septic shock 5, 19, 28 . In clinical trials on patients suffering from sepsis or ARDS, pre-treatment is impossible. However, it has been shown that major surgical procedures initiate a systemic inflammatory response and carry a risk of postoperative organ dysfunction leading to sepsis and MSOF 1, 2 . Therefore, we designed our study to assess the effects of N-acetylcysteine treatment given before and during surgery on early postoperative organ dysfunction. Nevertheless, we were unable to show improved respiratory, cardiac or other organ function despite encouraging results obtained by others 29 . This discrepancy could be explained by the different patient population. The sample size of this study was determined on the basis of our previous investigation on patients following oesophagectomy, whilst in the current trial only half of the patients had oesophageal surgery. Therefore, it is possible that the efficacy of treatment using the P a O 2 /FiO 2 ratio was overestimated. However, there was a similar decline in the P a O 2 /FiO 2 ratio in both groups with no significant difference. The regimen we used in this trial may have accounted for the lack of effect. The dose of N-acetylcysteine in previous investigations had varied from 40 mg.kg -1 .day -1 to >480 mg.kg -1 .day -1 . The dose used in our study was within this range, in accordance with the standard intravenous regimen for paracetamol-induced hepatic failure 10 . The possible disadvantage of excessive doses could be the formation of toxic intermediate molecules during N-acetylcysteine metabolism such as glutathionyl free radicals, glutathione disulfide and cysteine 28 . Studies again show a great variability with respect to length of treatment from one single bolus to six days of continuous treatment, with no evidence to support any of the applied methods 30 . We decided to treat our patients with an initial bolus followed by continuous infusion during surgery. However, extending the duration of the infusion for several days or changes in the dosage might have given a different result.
CONCLUSION
In this study short-term infusion of N-acetylcysteine during surgery failed to influence clinical outcome in patients with high-risk for postoperative organ dysfunction. As our sample size was relatively small, to investigate the impact of N-acetylcysteine on mortality, large multicentre trials are needed. However, our results do not support the prophylactic use of N-acetylcysteine in patients undergoing major abdominal surgery.
